<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04026711</url>
  </required_header>
  <id_info>
    <org_study_id>18-0564</org_study_id>
    <nct_id>NCT04026711</nct_id>
  </id_info>
  <brief_title>MitoQ for the Treatment of Metabolic Dysfunction in Asthma</brief_title>
  <acronym>MIMDA</acronym>
  <official_title>MitoQ for the Treatment of Metabolic Dysfunction in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 14-week, randomized, placebo-controlled, double-masked clinical trial in 40 obese patients&#xD;
      with poorly controlled asthma.&#xD;
&#xD;
      The intervention is Mitoquinol (MitoQ) versus placebo.&#xD;
&#xD;
      The primary aim of this pilot study is to determine if MitoQ improves airway reactivity in&#xD;
      obese patients with asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study aim:&#xD;
&#xD;
      The objective of this proposal is to conduct a pilot clinical trial to determine if the&#xD;
      mitochondrial-targeted anti-oxidant MitoQ improves airway reactivity in obese patients with&#xD;
      poorly controlled asthma.&#xD;
&#xD;
      Type of Study:&#xD;
&#xD;
      A 14 weeks, prospective, two center (Duke and the University of Vermont), randomized,&#xD;
      placebo-controlled, double-masked clinical trial.&#xD;
&#xD;
      Study Population:&#xD;
&#xD;
      40 patients with obesity and poorly controlled asthma.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      MitoQ 40 mg per day versus placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double masked study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>change in airway reactivity</measure>
    <time_frame>Through study completion, 12 weeks</time_frame>
    <description>airway reactivity to methacholine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 8-isoprostanes.</measure>
    <time_frame>Through study completion, 12 weeks</time_frame>
    <description>serum, sputum and nasal lavage 8-isoprostanes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sputum cell counts.</measure>
    <time_frame>Through study completion, 12 weeks</time_frame>
    <description>change induced sputum cell counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Test (ACT)</measure>
    <time_frame>Through study completion, 12 weeks</time_frame>
    <description>To collect data on asthma symptoms measured by asthma control questionnaire determined by a score from 5-25 (the lower the score, the worse the asthma symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>Through study completion, 12 weeks</time_frame>
    <description>pill counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma quality of life questionnaire.</measure>
    <time_frame>Through study completion, 12 weeks</time_frame>
    <description>The Marks Asthma Quality of Life Questionnaire (Marks AQLQ). Minimum score of 20, maximum score of 100. The greater the score, the more asthma is affecting quality of life. Minimum score is 5, maximum score is 35. The greater the score, the more severe the asthma symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Symptom Utility Index</measure>
    <time_frame>Through study completion, 12 weeks</time_frame>
    <description>The Asthma Symptom Utility Index (ASUI), a 2-week utility-weighted asthma symptom questionnaire. Used to collect data on frequency and severity of asthma symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function FEV1</measure>
    <time_frame>Through study completion, 12 weeks</time_frame>
    <description>FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function, FVC</measure>
    <time_frame>Through study completion, 12 weeks</time_frame>
    <description>FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in lung impedance</measure>
    <time_frame>Through study completion, 12 weeks</time_frame>
    <description>measured by forced oscillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>Through study completion, 12 weeks</time_frame>
    <description>assessed at each study visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Asthma</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>MitoQ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MitoQ 40 mg per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoquinol</intervention_name>
    <description>Mitoquinol (MitoQ) 40 mg per day for 12 weeks</description>
    <arm_group_label>MitoQ</arm_group_label>
    <other_name>MitoQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. participant reported physician diagnosis of asthma&#xD;
&#xD;
          2. participant reported on regular prescribed controller therapy for at least 3 months&#xD;
&#xD;
          3. positive methacholine challenge (as determined by PC20 ≤ 4.0 mg/ml at visit 2)&#xD;
&#xD;
          4. age: ≥18 years&#xD;
&#xD;
          5. BMI ≥ 30 kg/m2 (at visit 1)&#xD;
&#xD;
          6. poorly controlled asthma defined as one of the following:&#xD;
&#xD;
               1. Asthma Control Test5 Score ≤ 19 (at visit 1), or&#xD;
&#xD;
               2. Participant reported use of rescue inhaler on average &gt; 2 uses/week for preceding&#xD;
                  month, or&#xD;
&#xD;
               3. Participant reported nocturnal asthma awakening on average 1 or more times / week&#xD;
                  in preceding month, or&#xD;
&#xD;
               4. Participant reported ED/hospital visit or prednisone course for asthma in past&#xD;
                  six months&#xD;
&#xD;
          7. ability and willingness to provide informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. participant reported use of an investigational agent in the prior 30 days&#xD;
&#xD;
          2. participant reported physician diagnosis of chronic obstructive pulmonary disease&#xD;
&#xD;
          3. pregnancy and/or participant reported lactation&#xD;
&#xD;
          4. females of childbearing age who do not agree to practice an adequate birth control&#xD;
             method for the duration of the study (abstinence, combination barrier and spermicide,&#xD;
             or hormonal)&#xD;
&#xD;
          5. participant reported greater than 10 pack year smoking history&#xD;
&#xD;
          6. participant reported smoking conventional tobacco products (cigar, cigarette, &amp; pipes)&#xD;
             within the last 6 months&#xD;
&#xD;
          7. participant reported e-cigarette use more than 2x/week&#xD;
&#xD;
          8. participant unwilling to withhold e-cigarette use for the duration of the study&#xD;
&#xD;
          9. participant reported vaping more than 2x/week&#xD;
&#xD;
         10. participant unwilling to withhold vaping for the duration of the study&#xD;
&#xD;
         11. participant reported marijuana use (inhalation) more than 2x/week&#xD;
&#xD;
         12. participant unwilling to withhold marijuana use (inhalation) for the duration of the&#xD;
             study&#xD;
&#xD;
         13. participant reported sinus surgery performed ≤ 4 weeks from visit 1&#xD;
&#xD;
         14. participant reported eye surgery within the prior 3 months&#xD;
&#xD;
         15. participant reported use of the antioxidants idebenone or co-enzyme Q10 within 8 weeks&#xD;
&#xD;
         16. participant reported tendency to develop severe nose bleeds&#xD;
&#xD;
         17. FEV1 ˂ 60% predicted or &lt; 1.5 Liters at visit 1&#xD;
&#xD;
         18. participant reported treatment for asthma exacerbation in the previous 4 weeks&#xD;
&#xD;
         19. participant was not able to complete at least 50% of the days on the diary cards&#xD;
             returned at visit 2&#xD;
&#xD;
         20. other significant disease that in the opinion of the investigator would interfere with&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne E Dixon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivia Johnson, MS, RDN</last_name>
    <phone>802-847-2160</phone>
    <email>olivia.johnson@uvmhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Foss, BS, RRT, RPFT, CCRC</last_name>
      <phone>919-479-0861</phone>
      <email>catherine.foss@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Loretta Que, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Johnson, MS, RDN</last_name>
      <phone>802-847-2160</phone>
      <email>olivia.johnson@uvmhealth.org</email>
    </contact>
    <investigator>
      <last_name>Anne E Dixon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Anne Dixon</investigator_full_name>
    <investigator_title>Professor of Medicine, Director of Pulmonary and Critical Care Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

